Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140784 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices
A NA study, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 116
- Enrollment target
NCT06140784: Completed NA study, sponsored by Procter and Gamble.
NCT06140784 is a NA study that has completed, run by Procter and Gamble. The registered enrollment target is 116 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06140784, a NA study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect four different dentifrices have on gingivitis after 12 weeks of product use. The secondary objectives are to assess the effect four dentifrices, have on plaque and oral microbiome composition.
Primary Outcome
Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
Interventions
- DRUG 0.76% Sodium Monofluorophosphate Dentifrice
- DRUG 0.454% Stannous Fluoride Dentifrice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2023-09-02 |
| Est. Completion | 2023-12-10 |
| Phase | NA |
What the finished NCT06140784 record still lists
NCT06140784 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which 0.76% Sodium Monofluorophosphate Dentifrice is the first listed.
NCT06140784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06140784 about?
NCT06140784 is a clinical study titled "A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices". The primary objective of this study is to evaluate the effect four different dentifrices have on gingivitis after 12 weeks of product use. The secondary objectives are to assess the effect four dentifrices, have on plaque and oral microbiome composition.
What is the current status of trial NCT06140784?
This trial is currently completed. It is a NA study. The enrollment target is 116 participants. The study started on 2023-09-02. Estimated completion is 2023-12-10.
What interventions are being tested in trial NCT06140784?
The interventions under investigation include: 0.76% Sodium Monofluorophosphate Dentifrice (DRUG), 0.454% Stannous Fluoride Dentifrice (DRUG).
Who is sponsoring clinical trial NCT06140784?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06140784's enrollment target sits among peer trials
116 808th of 2000 higher than 1,191 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI